

SMART Methods Working Group: Harnessing Collective Expertise to Strengthen Signal Detection


Review of main Achievements

Cosimo Zaccaria (EMA)

Signal Management Review Technical Working Group

Collaboration between Member States and EMA with the objective to strengthen and simplify the signal management process in the EU.

SMART PROCESS




- Evaluation of signal management processes essential for effective and efficient operation.
- Identification of opportunities for improvement and reinforcing elements that work well

SMART METHODS



- Leveraging expertise and review methods in signal detection
- Facilitate further collaboration with Signal Management Experts
- Highlight the International aspect of the Collaboration



- **continuous process evaluation,**
- **exploration of new methodologies**
- **enhanced transparency**

SMART Methods: Operational aspects

Meetings and Participation

- Quarterly meetings
- Reports to PRAC on a quarterly basis
- Interaction with other forums
- Tracking tool and monitor progress & deliverables



EUROPEAN MEDICINES AGENCY
SCIENCE · MEDICINES · HEALTH

[Medicines](#) ▾ [Human regulatory](#) ▾ [Veterinary regulatory](#) ▾ [Committees](#) ▾ [News & events](#) ▾ [Partners & networks](#) ▾ [About us](#) ▾

[Home](#) > [Committees, working parties and other groups](#) > [Working parties and other groups](#)
> [Signal Management Review Technical \(SMART\) Working Group](#)

Signal Management Review Technical (SMART) Working Group

[Share](#)

The Signal Management Review Technical (SMART) Working Group is responsible for leveraging expertise in the field of signal management to strengthen and simplify related processes in the European Union (EU). The group is a collaboration between EU Member States and the European Medicines Agency (EMA).

[Corporate](#)

[Pharmacovigilance](#)



Co-chairs:

- **E. van Puijenbroek (Lareb)**
- **C. Zaccaria (EMA)**

Members

- **28 NCAs members**
- **12 EMA members**
- **4 WHO-UMC members**
- **2 academic centres**
- **1 Independent Experts**

SMART Methods Objectives

- **Leveraging** the group resources and its on-going initiatives
- Promoting **Interaction** with other forums
- Managing a **portfolio of initiatives** with different levels of engagement




Prioritise research areas



Review and Test new Methods



Validate and Implement Evidence-base methods




Communicate to ensure knowledge transfer




Key Drivers:

- **Ease of Development**
- **Ease of implementation and maintenance**
- **Ease of interpretation of results**
- **Significant impact on the overall process**


Some important achievements



Established Priorities



- **SafetyNet:** Support prioritisation of MedDRA Terms that are likely to be drug attributable: Designated Medical Events (DMEs) / Adverse Events of Special Interest (AESIs)




- **Signal Of Disproportionate Reporting:** Support automatic screening based on statistical tools



- **Weekly screening** of recent publications
- Review of safety communication from other jurisdictions

Reduce time to detection



Control False Positives



Complementary activity




Relevance of data sources



Origin of the reviewed Signals

- EV remains the main data source



- Spontaneous data remain the most valuable source of information for signal detection
- Literature screening increasingly important over time
- Combining data sources provides a more complete and reliable picture of emerging safety issues.

Workplan 2022-2025: Status

Completed Ongoing Not started

Scoping

defining objectives, potential methods & resources to be used

- Statistical Correction of Uncharacterised Bias (SCRUB)
- SMART Website

- Mechanism of Action (Drug-ADR Causal pathways)
- SSA

Further Exploration

expanding on initial findings, literature review for new hypotheses, investigate gaps and gain more insights

- Time-Series forecasting
- Pediatrics
- Geriatrics
- Abuse/Misuse of opioids
- MedDRA synonymous: Terms other than standard MedDRA for signal detection
- Drug interactions
- RWE for signal detection

Experimentation

design and execute tests to validate/reject approaches for implementation

AI Adjudication of cases



Signal Analytics (MNEMOSiNE)




Reference Dataset (EurEKA)




Priorities

ranking of research topics according to their importance, urgency and relevance


Observed to Expected




COVID-19 Masking effect



Pregnancy algorithm



Report clustering based on ADR profile



Lessons Learned on Observed-to-Expected Analysis Using Spontaneous Reports During Mass Vaccination

María Gordillo-Marañón^{1,2} · Gianmario Candore³ · Karin Hedenmalm¹ · Kate Browne⁴ · Robert Flynn^{1,5} · Loris Piccolo¹ · Aniello Santoro⁶ · Cosimo Zaccaria⁶ · Xavier Kurz¹

Objectives

- Define strategy to generate rapid evidence on AESIs for signal contextualisation

Deliverables

- ✓ **Forthnightly routine analyses shared with the network**
- ✓ **Descriptive analysis to improve coding terms and risk periods**
- ✓ **Publication of lessons learned**



Risk Period


Observed



Expected

Methods:

- Collect coverage data stratified by age and gender
- Define MedDRA strategy and coding
- Generate BGRs stratified by age and gender
- Compare observed data with expected



Key Aspects

- Understand strengths and limitation of this methodology
- Stratification and coding terms are critical
- Guidance updates


Masking Effect of Covid 19 vaccines

Objectives

- Assess the magnitude of the over-representation of Covid19 vaccines in EV


• Deliverables

- ✓ Create focus group
- ✓ Impact assessment
- ✓ Propose remediation strategies and easy to implement methods



Methods:

- Impact analysis using influential outliers
- Removal of Covid19 vaccines from ROR calculation
- Imbalance analysis between competing vaccines




Key Aspects

- Impact in small databases can be significant
- Impact on large databases is more moderate
- Alternative prioritisation approaches in signal detection can minimise this bias.
- Remediation approaches:
 - Identify most impacted events
 - Remove covid19 vaccines from denominator

Identification of Pregnancy Adverse Drug Reactions in Pharmacovigilance Reporting Systems: A Novel Algorithm Developed in EudraVigilance

Cosimo Zaccaria¹  · Loris Piccolo¹  · María Gordillo-Marañón²  · Gilles Touraille¹  · Corinne de Vries¹ 



Objectives

- Identify data elements that are likely to hold pregnancy information in ICSRs and develop an algorithm

Deliverables


-  Create a focus group
-  Publish the algorithm
-  Implement the algorithm in EVDAS + Dashboarding
-  Support GVP Pregnancy and Breastfeeding

Methods:

- Validate the algorithm (90%PPV) against the SMQ 'Pregnancy and Neonatal Topics' (54%PPV)
- Compare EMA algorithm with other existing algorithm

Key Aspects

- Co-reporting 'maternal exposure during pregnancy' and Route of Administration : transplacental is important to improve data retrieval
- The algorithm is focussed on ADR during pregnancy to further supports signal detection activities



Leveraging 20 years of EMA signal records: An overview of drug interaction signals with MNEMOSiNE

Maria Mantziri¹, Elpida Kontsioti¹, Julie Durand¹, Viola Macolic Sarinic¹, Cosimo Zaccaria¹

Objectives

- Describe DI signals in Mnemossine (historical knowledge from 27k EMA reviewed signals)


Deliverables

- ✓ DI signals were identified and described
- ✓ Use of Mnemosine as an asset to generate insight on DI signals




Methods:

- Extract DI signals from 2004-2023
- Review regulatory outcomes of DI validated signals



Key Aspects

- Literature remains key for detecting DI signals
- Majority coded as general medical events or general interaction complicating mechanistic interpretation
- Further SD efforts may benefit from incorporating biological and omics data



Poster presented at the ISoP Cairo 2025 <https://isop2025cairo.org/>





Geriatrics

Objectives

- Identify elements that might be used to strengthen the prediction of highly age specific effect

Deliverables

- ☒ Implementation of relative geriatric ROR in eRMR



Paediatrics

Objectives

Identify elements that might be used to strengthen the prediction of paediatric ADRs

Deliverables

- ☒ Creation of paediatric Targeted Medical Events TME list
- ☒ eRMR Implementation of paediatric TMEs
- ☒ Implementation of relative paediatric ROR in eRMR
- ☐ Further validation of TMEs list is needed



Potential New Opportunities

- New insights from AI
- Leverage DDIs algorithms
- Leverage RWE
- Provide input to GVP


Abuse/Misuse/Med. Error/Overdose

Objectives

- Assess new methods for better monitoring

Deliverables

- ☒ Descriptive analysis on overdose, medication error, abuse and misuses in EV with opioids
- ☐ Propose routine reports of monitoring of opioid trends




Time-Series Analysis

Objectives

- Create a model to detect unexpected increases in frequency UIF
- Validate the tool

Deliverables

- ☒ Validation of the tool & Publication
- ☐ Further prospective validation



An algorithm to detect unexpected increases in frequency of reports of adverse events in EudraVigilance

[Luis C Pinheiro](#)^{1,✉}, [Gianmario Candore](#)¹, [Cosimo Zaccaria](#)¹, [Jim Slattery](#)¹, [Peter Arlett](#)¹



Potential New Opportunities

- Advance technologies
- AI for pattern identification


MedDRA Synonymous

Objectives

- Test methods to identify groups of terms other than standard MedDRA hierarchy for statistical SD

Deliverables

- ☒ Consider UMC work on vector representation of AE
- ☐ Prospective validation of the tool for implementation




Mechanism of Action

Objectives

- Identify pathway elements that might be used to predict ADRs

Deliverables


- ☒ Identify sources of data
- ☐ Prediction models to be tested



Potential New Opportunities

- Advance technologies
- AI for pattern identification

Key Performance Metrics in Signal Detection



Regulatory Actions

Signal Confirmation

Signal Validation

Signal Detection



Regulatory action Rate / Publications / Guidelines:

Assess ability to mitigate risks and respond quickly to emerging issues and overall efficiency in the signal detection process




Quality of Individual cases reviewed

This metric, together with the n ADRs screened and signals reviewed, reflect the overall workload and quality of reports



Average of individual cases reviewed to validate a signal

This metric reflect the overall complexity in the signal validation process



Time to Detection from first report received / flagged as a priority

This metric provides insight of the effectiveness of signal detection

Feedback from SMART Methods Members

Smart Input



Current Focus



Priorities



Support




Feedback

Learnings

Collaborate


Improve



FUTURE AREAS TO PRIORITISE

1. **Responsible Use of AI in PV**
2. **Better integration of RWE**
3. **Better Collaboration, training and Communication**

Use of AI and automation in EMA signal detection workflow



Internal Digital Innovation Team (HDL)

Projects

1. Literature screening for ICSRs (OWLS)
2. eRMR production
3. Literature screening for signals (ERATO)
4. ADR data extraction (EurEKA)
5. AI-enhanced case adjudication (AERGIA)
6. Insight generation from historical reviews (MNEMOSiNE)

Status

- (Pilot-)deployed
- Ongoing / upcoming

Integration of Other Data Sources

Routine use



Spontaneous reports



Clinical trial reports



Literature reports



EPARs, RMPs, PSURs



Historical signal records

EudraVigilance
Scientific literature
Regulatory documents...

Emerging or occasional use



Electronic health records



Hospital data



Insurance claims



Registries



Medicines information



Vaccination coverage

DARWIN EU®
ECDC
MedicinesComplete...

Potential use



Omics



Chemical structures,
systems pharmacology



Social media posts



Mobile health data



Patient experience

EU-SRS, DrugBank
Social media
Mobile devices...


Final remarks



Research Achievements

Crucial Role of SMART in reviewing and implementing a wide range of emerging methods

Covid-19 pandemic has created an unprecedented need for methodological standards and fast generation of high-quality evidence to support regulatory and public health decision-making



New Opportunities

Leverage AI in Pharmacovigilance

Integration of RWE for signal contextualisation

Facilitate both bilateral and multilateral collaboration to accelerate progress

Collaborative effort: transforming Data Into Tangible
Public Health Outcomes





EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Thank you

Follow us

